Omni Peptides
Tesamorelin
Couldn't load pickup availability
GHRH analog; strongest visceral/abdominal fat burner, clean GH/IGF-1 boost
Tesamorelin (also known as TH9507) is a synthetic 44-amino-acid polypeptide analog of human growth hormone-releasing hormone (GHRH), featuring an N-terminal modification with a trans-3-hexenoyl group for enhanced stability and resistance to enzymatic degradation. This research compound has garnered significant scientific interest for its ability to stimulate pulsatile endogenous growth hormone (GH) secretion from the anterior pituitary, thereby elevating insulin-like growth factor-1 (IGF-1) levels and influencing metabolic pathways. Preliminary and advanced preclinical studies indicate that tesamorelin may promote lipolysis, reduce visceral adipose tissue, support muscle preservation, and modulate body composition. Researchers employ this peptide in laboratory and animal models to investigate mechanisms of GH axis regulation, fat metabolism, and endocrine responses, particularly in models of metabolic dysregulation and age-related decline. As a research-grade compound, tesamorelin is intended exclusively for in vitro and animal studies. Scientists value its improved pharmacokinetic profile over native GHRH and its utility in elucidating targeted GH stimulation without direct exogenous hormone administration.
Research Applications
Storage & Handling
Storage & Handling
Lyophilised vials are stable at −20°C for up to 2 years unopened. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.
Beyond Use Date
Pre-filled formats (cartridge, pen, nasal) carry a beyond-use date of typically 4–8 weeks from receipt. ≥98% purity by HPLC. For in vitro and preclinical research use only — not for human or veterinary use.
— About this compound
Tesamorelin is a synthetic growth-hormone-releasing factor analogue.
Tesamorelin (also known as TH9507) is a synthetic 44-amino-acid polypeptide analog of human growth hormone-releasing hormone (GHRH), featuring an N-terminal modification with a trans-3-hexenoyl group for enhanced stability and resistance to enzymatic degradation. This research compound has garnered significant scientific interest for its ability to stimulate pulsatile endogenous growth hormone (GH) secretion from the anterior pituitary, thereby elevating insulin-like growth factor-1 (IGF-1) levels and influencing metabolic pathways. Preliminary and advanced preclinical studies indicate that tesamorelin may promote lipolysis, reduce visceral adipose tissue, support muscle preservation, and modulate body composition. Researchers employ this peptide in laboratory and animal models to investigate mechanisms of GH axis regulation, fat metabolism, and endocrine responses, particularly in models of metabolic dysregulation and age-related decline. As a research-grade compound, tesamorelin is intended exclusively for in vitro and animal studies. Scientists value its improved pharmacokinetic profile over native GHRH and its utility in elucidating targeted GH stimulation without direct exogenous hormone administration.
Research Applications
Where researchers apply it.
— Verified & Documented
Every vial is backed by a Certificate of Analysis.
Each lot is independently characterised by HPLC and mass spectrometry, with identity, mass and purity documented per batch and available on request.
Additional quality-control testing, including sterility, endotoxin and heavy metals, is conducted periodically across our product range.
Storage & Handling
Storage & Handling
Lyophilised vials are stable at −20°C for up to 2 years unopened. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.
Beyond Use Date
Pre-filled formats (cartridge, pen, nasal) carry a beyond-use date of typically 4–8 weeks from receipt. ≥98% purity by HPLC. For in vitro and preclinical research use only — not for human or veterinary use.